Industry LBO execution

How to model an LBO for UK Pharma Services assets

Direct answer

For UK Pharma Services buyouts, the LBO model should anchor on billable scientist utilization and explicitly stress client trial delays plus regulatory audit findings. Underwriting quality comes from converting operating assumptions into cash conversion cases, then testing debt service under downside, base, and control-upside scenarios.

Core risk factors

  • Client trial delays
  • Regulatory audit findings
  • Concentrated biotech exposure

Execution baseline

Metric to anchor underwriting: Billable scientist utilization

Modelling focus: Project timing and cancellation downside

Move from theory to execution

This guide is an orientation layer. The Principal Programme runs these judgments on a target universe you chose, with written deliverables and a live investment committee vote.

Read the PGPTry Day One Simulator